Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  MedicationType 2 DiabetesIssue 576GLP-1 Series Issue 1GLP-1 Series Issue 3GLP-1 Series Issue 4GLP-1 Series Issue 5GLP-1

Sanofi's Once Daily GLP-1 Lyxumia ® Meets Primary Endpoint in Phase 3 Study

Lyxumia (lixisenatide) when used as an add-on therapy to basal insulin (in association with or without metformin), achieved its primary efficacy endpoint of significantly reducing HbA1c versus placebo for patients with type 2 diabetes without significantly increasing their risk of hypoglycemia....

Advertisement

Sanofi announced that its GetGoal-L is one of nine studies in the GetGoal phase III clinical program, and the second trial to investigate the benefits of lixisenatide 20µg once-daily combined with basal insulin. It was a randomized (double-blind), placebo-controlled study with a 24-week main treatment period, and a total of 495 patients received either lixisenatide or placebo.

GetGoal-L showed a significant reduction in HbA1c levels (p=0.0002) with lixisenatide, without a significant increase in the incidence of symptomatic hypoglycemia (p=0.14) versus placebo. In addition, patients treated with lixisenatide had significantly improved postprandial plasma glucose after a test meal (p<0.0001). Patients in the lixisenatide arm of the study also reported a significant reduction in body weight (p<0.0001). These results confirm those previously reported on GetGoal-L Asia, this time in a broader population including both Caucasian and Asian patients. As expected with a GLP-1, the most commonly reported adverse event with lixisenatide was nausea with a low rate of discontinuation.

"These positive efficacy and safety results are another important milestone in the GetGoal clinical trial program and show the potential value of adding Lyxumia (lixisenatide) to basal insulin to improve glycemic control," said Pierre Chancel, senior vice president, Global Diabetes Division at Sanofi. "The findings from this and previous studies reinforce a continuing positive trend demonstrating the potential of lixisenatide to improve the lives of people with type 2 diabetes."

The full study results from GetGoal-L are planned to be presented at a medical congress.

Lixisenatide, a Glucagon-Like Peptide-1 agonist (GLP-1), is in development for the treatment of patients with type 2 diabetes mellitus. Lixisenatide was in-licensed from Zealand Pharma A/S (Copenhagen, Denmark).

The GetGoal phase III clinical program will provide data for the efficacy and safety of lixisenatide in adults with type 2 diabetes treated with various oral anti-diabetic agents or insulin. With nine trials in the program, GetGoal started in May 2008 and has enrolled more than 4300 patients. To date GetGoal-X, GetGoal-Mono, GetGoal-L Asia and GetGoal-S have reported positive top-line results supporting efficacy and safety for lixisenatide. Further results are expected during 2011.

Sanofi News Release June, 2011

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 01 June, 2011 and appeared in  MedicationType 2 DiabetesIssue 576GLP-1 Series Issue 1GLP-1 Series Issue 3GLP-1 Series Issue 4GLP-1 Series Issue 5GLP-1

Past five issues: Issue 783 | SGLT-2 Inhibitors Special Edition May 2015 | Diabetes Clinical Mastery Series Issue 242 | Issue 782 | GLP-1 Special Editions May 2015 |

2015 Most Popular Articles:

What Is the Medicare Diabetes Prevention Act?
Posted May 08, 2015
Neuropathy Due to Vitamin B-12 Deficiency, Not Diabetes
Posted April 30, 2015
Is Diet or Exercise the Best Way to Reduce Diabetes Risk?
Posted May 15, 2015
GLP-1 Analog May Help with NAFLD and Nonalcoholic Steatohepatitis
Posted May 15, 2015
Fish Oil May Help with Diabetic Neuropathy
Posted May 15, 2015
SGLT-2 Inhibitors: Teach from the Start and Manage Expectations
Posted May 03, 2015
Vitamin D Supplements May Help Patients Lose Weight
Posted May 15, 2015
Treating Sleep Apnea with CPAP Nightly Can Lower Diabetes Risk
Posted May 08, 2015
Summary of Standards of Care for Diabetes for Primary Care
Posted April 30, 2015
Metformin Reported in Use with Only 3.7% of Those with Prediabetes
Posted April 30, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Do you believe that the FDA takes too much time to approve a drug?
CME/CE of the Week
Category: Nutrition
CE Credits: .5



Search Articles On Diabetes In Control